Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results37

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results28

Views

Views
November 20243
December 20240
January 20255
February 20253
March 202515
April 20252
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United Kingdom6
United States4
Lithuania2
Spain1
 

Top cities views

Views
London2
Council Bluffs1